당뇨황반부종에 대한 트리암시놀론의 유리체강내 주입술과 테논낭하 주입술의 비교 = Intravitreal Versus Subtenon Injections of Triamcinolone Acetonide for Diabetic Macular Edema

다국어 초록 (Multilingual Abstract)

`Purpose: To retrospectively evaluate the clinical effect of intravitreal (IVT) and posterior subtenon (PSTT) triamcinolone acetonide (TA) injection in diabetic macular edema. Methods: Fifty eyes of 43 patients with diabetic macular edema (DME) were included. Twenty-two eyes in the IVT group received 4 mg/0.1 ml intravitreal TA injections and 26 eyes in the PSTT group received 40 mg/1.0 ml subtenon TA injections. LogMAR visual acuity and intraocular pressure (IOP) were measured and, using OCT, central macular thickness (CMT) and total macular volume (TMV) were also measured before and 1, 3, and 6 months postoperatively. Results: Both groups showed significant decreases in the mean CMT and TMV. The mean CMT in the IVT group was significantly thinner than that of the PSTT group 1 month postoperatively. The percentage reduction in CMT and TMV were also greater in the IVT group than the PSTT group 1 month postoperatively. Both groups showed significant improvements in mean visual acuity, with no significant difference between the two groups. However, at 1-month postoperative improvement in visual acuity was significantly greater in the IVT group than the PSTT group. The mean IOP in the IVT group was also greater than that in the PSTT 1 month postoperatively. Conclusions: Both injections caused a significant increase in visual acuity and a decrease in CMT and TMV. The effect was more pronounced in the IVT group. However, the PSTT injection also appeared to be a safe and effective technique for the treatment of DME.`

참고문헌 (Reference)

1 양연희, "유리체내 트리암시놀론 주사 후 안압의 변화" 대한안과학회 45 (45): 1081-1085, 2004

2 박현준, "유리체내 트리암시놀론 주사 후 발생한 비감염성 안내염 1예" 대한안과학회 46 (46): 1419-1423, 2005

3 김인철, "난치성 당뇨황반부종에 대한 유리체내 Triamcinolone Acetonide 주입의 임상적 효과" 대한안과학회 45 (45): 228-236, 2004

4 Ambati J, "Transscleral delivery of bioactive protein to the choroid and retina" 41 : 1186-1191, 2000

5 Okada AA, "Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis" 87 : 968-971, 2003

6 McCuen BW, "The lack of toxicity of intravitreally administered triamcinolone acetonide" 91 : 785-788, 1981

7 Helm CJ, "The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis" 120 : 55-64, 1995

8 Bakri SJ, "The effect of intravitreal triamcinolone acetonide on intraocular pressure" 34 : 386-390, 2003

9 Mueller AJ, "The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure" 125 : 158-163, 1998

10 Abel AD, "Sclerosing lipogranuloma of the orbit after periocular steroid injection" 110 : 1841-1845, 2003

11 Gillies MC, "Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial" 122 : 336-340, 2004

12 Young S, "Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis" 29 : 2-6, 2001

13 Moshfeghi DM, "Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection" 134 : 132-134, 2002

14 Bakri SJ, "Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema" 139 : 290-294, 2005

15 Tanner V, "Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis" 12 : 679-685, 1998

16 Tunc M, "Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema" 112 : 1086-1091, 2005

17 Aurden F, "Pharmacokinetic- pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema" 45 : 3435-3441, 2004

18 Pitkanen L, "Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity" 46 : 641-646, 2005

19 Nozik RA, "Periocular injection of steroids" 76 : 695-705, 1972

20 Jordan DR, "Orbital mass following injection with depot corticosteroids" 36 : 153-155, 2001

21 Schindler RH, "Machemer R. The clearance of intravitreal triamcinolone acetonide" 93 : 415-417, 1982

22 Hayashi K, "Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion" 139 : 972-982, 2005

23 Antcliff RJ, "Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study" 108 : 765-772, 2001

24 Benhamou N, "Intravitreal triamcinolone for refractory pseudophakic macular edema" 135 : 246-249, 2003

25 Martidis A, "Intravitreal triamcinolone for refractory diabetic macular edema" 109 : 920-927, 2002

26 Sutter FK, "Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial" 111 : 2044-2049, 2004

27 Danis RP, "Intravitreal triamcinolone acetonide in exudative age-related macular degeneration" 20 : 244-250, 2000

28 Greenberg PB, "Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion" 86 : 247-248, 2002

29 Massin P, "Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial" 111 : 218-224, 2004

30 Jonas JB, "Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy" 13 : 468-473, 2003

31 Smithen LM, "Intravitreal triamcinolone acetonide and intraocular pressure" 138 : 740-743, 2004

32 Jonas JB, "Intraocular pressure elevation after intravitreal triamcinolone acetonide injection" 112 : 593-598, 2005

33 Jonas JB, "Intraocular pressure after intravitreal injection of triamcinolone acetonide" 87 : 24-27, 2003

34 Beer PM, "Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection" 110 : 681-686, 2003

35 Kaushik S, "Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion" 137 : 758-760, 2004

36 Nelson ML, "Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection" 23 : 686-691, 2003

37 Machemer R, "Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye" 16 : 166-167, 1996

38 Challa JK, "Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up" 26 : 277-281, 1998

39 Benz MS, "Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone" 121 : 271-273, 2003

40 "Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2" 94 : 761-774, 1987

41 "Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1" 103 : 1796-1806, 1985

42 "Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19" 113 : 1144-1155, 1995

43 Jonas JB, "Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema" 121 : 57-61, 2003

44 Ciulla TA, "Corticosteroids in posterior segment disease: An update on new delivery systems and new indications" 15 : 211-220, 2004

45 Melberg NS, "Corticosteroid-induced ocular hypertension in the treatment of aphakic or pseudophakic cystoid macular edema" 100 : 164-167, 1993

46 Cardillo JA, "Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema" 112 : 1557-1563, 2005

47 Kalina PH, "Biochemical quantification of triamcinolone in subconjunctival depots" 113 : 867-869, 1995

48 Moshfeghi DM, "Acute endophthalmitis following intravitreal triamcinolone acetonide injection" 136 : 791-796, 2003